Why I’m Skeptical of the NAD+ Hype (And What the Human Evidence Actually Shows)
A pseudonymous reader walks through the human trials behind NAD+, NMN, and NR, and explains why the gap between the marketing and the outcome data is the biggest red flag in the longevity space right now.
by JoyBoy
11 min read
Last reviewed May 2026
🟡 Human Observational + small RCTs (precursors)
Sold as supplement. IV/injectable forms compounded under varying frameworks.
Why I looked into this
NAD+ is everywhere right now. IV drips at wellness lounges. Capsules in the longevity influencer’s morning routine. Patches, sublinguals, nasal sprays. The pitch is the same across all of them: cellular renewal, mitochondrial youth, energy, mood, sometimes outright “anti-aging.” And the price tag is rarely small.
I went looking for the human trials behind those claims because I keep getting asked about NAD+ on this site. I am writing this as a skeptic who tried to be fair. I read the precursor RCTs, the few human IV studies that exist, the FDA actions on NMN, and the longevity-influencer literature. I came away unconvinced, and I am going to show my work.
One thing up front: I have not used NAD+ in any form. No IV, no NMN, no NR. This piece is opinion based on reading, not experience. I am explicit about that because I think the line matters.
What NAD+ actually is (and a scope note)
Quick scope note before anything else: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It does not belong on a peptide site by chemistry alone. It is here because the marketing world packages it as a sibling of the peptide longevity category, and the same wellness clinics and gray-market channels that move research peptides also move NAD+ products. If you are reading peptide content, you are seeing NAD+ ads. So I am going to address it.
NAD+ itself is a small molecule that every living cell makes and uses. It is a cofactor for hundreds of metabolic reactions, including the ones that turn food into ATP and the ones that activate sirtuins (a family of proteins that the longevity world has spent two decades getting excited about). NAD+ blood levels decline with age. That fact is real. The question is what to do with it, and what raising those levels actually achieves for a human.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors. You take them by mouth. They are converted to NAD+ inside cells. Both have been shown in human trials to raise circulating NAD+ levels. That is the part of the story that is on solid ground. Everything past it gets thinner fast.
What the human research shows
Do NMN and NR actually raise human NAD+ levels?
Yes. This is the cleanest finding in the whole space. Small Phase 1 and Phase 2 trials in humans have repeatedly shown that oral NMN and oral NR increase blood NAD+ concentrations in a measurable way.
- Trammell et al, Nat Commun 2016: single-arm human pharmacokinetic study of NR, n=12, demonstrated amount-related increases in blood NAD+. Industry funded (ChromaDex).
- Martens et al, Nat Commun 2018: randomized crossover trial of NR in healthy middle-aged and older adults, n=24, NR raised NAD+ and modestly reduced systolic blood pressure. Mixed funding.
- Yoshino et al, Science 2021: randomized placebo-controlled trial of NMN in postmenopausal women with prediabetes, n=25, NMN raised NAD+ markers and improved muscle insulin sensitivity. Academic funded.
- Yamaguchi et al and others, 2022 to 2024: a growing list of small NMN RCTs, generally n under 100, generally 8 to 12 weeks, generally measuring blood NAD+, walking speed, grip strength, sleep quality, or fatigue scores.
Does raising NAD+ produce the outcomes the marketing claims?
This is where I get skeptical. The trials that exist are mostly short (8 to 12 weeks), small (n under 100), measure surrogate endpoints (NAD+ blood levels, walking speed, insulin sensitivity), and report mixed effects on the things people actually pay for NAD+ to do.
What the precursor trials have NOT shown:
- That raising NAD+ extends lifespan in humans. There is no human longevity outcome trial. There cannot be one yet at the relevant scale.
- That raising NAD+ rolls back, slows, or otherwise alters age-related cognitive decline. The cognitive endpoints in the trials are mostly null or mixed.
- That the energy and mood claims used in marketing copy are supported by clinically meaningful effect sizes in placebo-controlled human work.
- That oral precursors are equivalent to IV NAD+. They are different products with different pharmacokinetics, marketed under one umbrella term.
What does the IV NAD+ research actually look like?
Thin. I went looking for placebo-controlled human RCTs of IV NAD+ on anti-aging endpoints, and I came up nearly empty. There are case reports. There are small open-label series in addiction medicine. There are clinic-published “outcomes” with no control group and no blinding. There is not a single rigorous, placebo-controlled, large-scale human RCT of IV NAD+ for the longevity, energy, or “cellular renewal” claims that drive the wellness market.
That is a remarkable evidence gap given how mainstream the IV product has become. People are paying hundreds of dollars per session for a wellness ritual whose outcome data, in humans, on the things they are buying it for, basically does not exist in the rigorous trial literature.
Where the hype came from (and why it is louder than the data)
The NAD+ marketing wave has three roots and they reinforce each other.
Root one: real biology. NAD+ is genuinely involved in metabolism, sirtuin activation, DNA repair signaling, and a long list of cellular housekeeping functions. NAD+ blood levels do decline with age. That is real. That is also a long way from “supplementing precursors makes the cells younger.” The biology being real is not the same as the intervention working.
Root two: a charismatic researcher narrative. A small number of high-profile longevity researchers spent years talking about NAD+ in the popular press. Books were written. Podcasts were filmed. Investments were made. Some of those researchers had financial relationships with NAD+ supplement makers. None of that proves the science is wrong. It does mean the volume of the message has not been calibrated to the actual size of the human effect.
Root three: a perfect product-market fit for wellness clinics. IV NAD+ is expensive, repeatable, gives the patient an immediate sensation (warmth, sometimes nausea, sometimes “energy”), and does not require any traditional medical justification. It is exactly the kind of product that fills a wellness IV clinic schedule. The economic incentive to keep the product in circulation is large. The incentive to fund a definitive placebo-controlled trial that might kill the golden goose is small.
None of those three roots are evidence. They are reasons the hype exists. The trial data is the only thing that actually answers the question of whether the product does what it says, and the trial data is limited, mostly biomarker-based, and largely silent on the outcomes the marketing leads with.
FDA and legal status
Sold as a dietary supplement until late 2022, when the FDA took the position that NMN had been investigated as a drug and was therefore excluded from the dietary supplement definition. The status remains contested as of 2026. Some brands continue to market it. The legal posture is genuinely unsettled.
Sold as a dietary ingredient. NR has had GRAS notification and is more widely accepted as a supplement than NMN. Marketed by multiple supplement makers (whom I do not name).
Not FDA-approved as a longevity intervention. Compounded by some 503A pharmacies and administered through wellness clinics or telehealth providers under varying frameworks. The framework is not the same as the established 503A compounding pathway for shortage-list drugs. Quality control and oversight vary widely.
FDA does not approve anti-aging claims for any supplement or compounded product. Marketing copy that promises “cellular renewal”, “biological age reversal”, or similar is operating in claim territory the FDA does not allow on a label. That does not mean those products are illegal to sell. It does mean the loud claims are unregulated marketing.
The legal posture for NMN specifically is a moving target. The FDA’s 2022 position created uncertainty that has not fully resolved. The market continues to operate around the ambiguity. None of that is the same as a clean regulatory green light.
I built a doctor visit-prep one-pager for the longevity supplement conversation. Evidence summary, what to ask before spending real money, how to read a clinic’s pitch. Free PDF. No upsell.
Get the longevity visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- For oral NR or NMN: a known supplement maker with third-party testing posted on the product page
- For IV NAD+: a clinic with a licensed prescribing clinician who is willing to walk you through the actual evidence
- A clinic that names the compounding pharmacy and is willing to share the certificate of analysis
- Honest framing about what the product does and does not do, including the gap between biomarker effects and outcome claims
- A clinician who is willing to say “this is probably not worth your money for your situation”
Red flags
- Anti-aging or “biological age reversal” language as the primary marketing claim
- “Doctors don’t want you to know” or any flavor of conspiracy framing
- Refusal to provide a certificate of analysis on a compounded IV product
- Influencer affiliate codes layered on top of the medical claim (especially when the influencer is also the brand owner)
- Bundling NAD+ with peptides being marketed as research-use-only
The wrinkle for NAD+ specifically
The marketing has lapped the science by a wide margin. That is the wrinkle. It is not that the molecule is dangerous. It is that the product category, especially in the IV form, is one of the easiest in wellness to sell on a story that the trial data does not support. A good source will be willing to talk about that gap. A bad one will get defensive when you bring it up.
Cost reality
IV NAD+ at a wellness clinic regularly runs several hundred dollars per session, with multi-session “courses” pushing the total into four figures. Oral NMN is a fraction of that and far more studied. The cost-to-evidence ratio of IV NAD+ is, in my opinion, the worst in the longevity supplement space. There is no free lunch in this transaction either.
Questions worth asking any source
What is the human RCT evidence for the specific claim you are making? What is in the IV bag exactly, and where is it compounded? Who is the prescribing clinician of record, and what is their scope of practice? What is the realistic effect size in the trials you are citing? A real source has answers. A bad one has a sales pitch with longevity science vocabulary in it.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself when I read a wellness clinic’s pitch.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of this molecule. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
I have not used NAD+ in any form. No IV, no NMN, no NR. My skepticism is not based on a bad personal experience. It is based on reading the trials and reading the marketing side by side and watching the gap between them widen every quarter. That gap is what I trust the least.
“The molecule is real. The biology is interesting. The marketing claims are running ten years ahead of the outcome data.”
If I had a friend asking, I would say the precursor data on NMN and NR is genuinely real, but the effects in the trials are modest, mostly on biomarkers, and a long way from the “anti-aging miracle” story. The IV product is the part I am most skeptical about. The price-to-evidence ratio is awful. The marketing is the loudest in the longevity space, and the rigorous trial data on the actual outcome people are buying it for is, in 2026, basically not there.
“The IV NAD+ product is the most marketing-driven and least evidence-backed corner of the longevity supplement world right now. That is my opinion, and I am willing to defend it.”
I am open to being wrong. If a large, placebo-controlled, long-duration human RCT comes out next year showing that IV NAD+ moves a hard endpoint in a clinically meaningful way, I will say so on this site and update this article. Until then, my honest read is that the hype is the product, the molecule is the costume, and the gap between the two is what people are actually paying for.
Questions to ask your doctor (or the wellness clinic)
If you are considering NMN, NR, or IV NAD+ for any longevity, energy, or cognitive claim, here are the questions I would want answered before spending real money, in order.
- Which specific human RCT supports the claim you are making? Not a mouse study. Not a mechanism paper. A randomized, placebo-controlled human trial. If the answer is vague, that is the answer.
- What was the effect size and on what endpoint? A statistically significant change in a blood biomarker is not the same thing as feeling better, living longer, or aging more slowly. Ask which the trial actually measured.
- Is this oral, IV, or another route, and why does that matter? Pharmacokinetics differ. Most of the human trials are on oral precursors. The IV product is a separate question with much thinner data.
- If this is IV NAD+, which compounding pharmacy made the product and can I see the certificate of analysis? A legitimate clinic will have this on file. Ask for it.
- What is the cost over a realistic course of use, and how does that compare to better-evidenced interventions? Sleep, training, basic labs, and a real clinician relationship usually do more. They are also less marketable.
- What would change your recommendation? A clinician who cannot articulate what would shift their view is selling, not advising. The same goes for the wellness clinic at the front desk.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the precursor RCTs themselves before reading the marketing. The papers are short. The effect sizes are modest. The endpoints are mostly biomarkers. That is the cleanest education available in this space.
Browse the monograph index →If you are considering
Have the conversation with a clinician you can actually reach, not the wellness clinic that benefits from the sale. Bring the visit-prep packet. Bring the cost-to-evidence question.
Get the visit-prep packet →If you have decided
Use the source-safety checklist before committing to any IV clinic, supplement maker, or telehealth provider. The marketing in this space is unusually loud and the certificates of analysis are unusually scarce.
Download the source-safety checklist →Sources
- Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. Industry funded (ChromaDex).
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. Mixed funding.
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-1229. Academic funded.
- Yamaguchi S, et al, and related 2022 to 2024 NMN RCTs in healthy adults; collectively n under 100 each, durations 8 to 12 weeks, biomarker endpoints predominant. Mixed funding.
- US FDA. Position on NMN as a dietary supplement ingredient, 2022 actions and subsequent correspondence. Status contested as of 2026.
- Reviews of IV NAD+ clinical evidence in addiction medicine and wellness contexts, noting the absence of large, placebo-controlled, anti-aging-endpoint trials.
Funding for the precursor trials is a mix of academic and industry, with several of the most cited papers tied to NAD+ supplement makers. Industry funding does not invalidate the data, but it is part of how the data should be read, especially when the marketing claims are this expansive.
Related monographs
MOTS-c
Mitochondrial peptide with the rodent data running ahead of the human evidence. Same shape of hype curve.
Epitalon
Longevity peptide whose marketing also outpaces the available human trial evidence.
Glutathione
Another wellness-clinic IV staple. I wrote up what the human data does and does not show.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.